Eledon’s Tegoprubart Improves Quality of Life Versus Tacrolimus in Phase 2 Kidney Transplant Trial

Bitget2026/10/26 11:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Eledon Pharmaceuticals announced Phase 2 BESTOW trial results showing sustained quality-of-life benefits with investigational tegoprubart versus tacrolimus in kidney transplant recipients.
Tegoprubart reduced transplant-related symptom burden through 12 months; tacrolimus recipients reported slightly worse symptom occurrence than at baseline.
Quality-of-life improvements included clinically and statistically significant benefits in symptoms and problems compared with tacrolimus.
Results were presented Oct. 23, 2026, at the American Society of Nephrology Kidney Week meeting in Denver.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eledon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260700PRIMZONEFULLFEED9852807) on October 26, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to reports, the trading firm JonesTrading is marketing up to $500 million worth of stock shares on behalf of some investors, at a 3% to 5% premium over the IPO issue price. This indicates that investors are already transferring their anticipated IPO allotted shares before the IPO is officially issued.

华尔街见闻•2026/11/10 23:03